Literature DB >> 35776189

Metabolomic profiling relates tianeptine effectiveness with hippocampal GABA, myo-inositol, cholesterol, and fatty acid metabolism restoration in socially isolated rats.

Ivana Perić1, Marija Lješević2, Vladimir Beškoski3, Milan Nikolić3, Dragana Filipović4.   

Abstract

RATIONALE: Discovering biomarkers of major depressive disorder (MDD) can give a deeper understanding of this mood disorder and improve the ability to screen for, diagnose, and treat MDD.
OBJECTIVES: In this study, metabolomics was used in unraveling metabolite fluctuations of MDD and drug outcome by creating specific metabolomic fingerprints. We report metabolomic patterns of change of the hippocampus of adult male Wistar rats following chronic social isolation (CSIS) (6 weeks), an animal model of depression, and/or chronic tianeptine (Tian) treatment (10 mg kg-1 per day) (lasting 3 weeks of 6-week CSIS), monitored by using comprehensive GC × GC-MS.
RESULTS: The comparative metabolomic analysis highlighted the role of gamma aminobutyric acid (GABA), iso-allocholate, and unsaturated fatty acid metabolism alterations following the CSIS, which was corroborated with moderate to strong negative Pearson's correlation of GABA, docosahexaenoic, 9-hexadecenoic acid, 5,8,11,14-eicosatetraynoic, and arachidonic acids with immobility behavior in the forced swim test. The antidepressant effect of Tian restored GABA levels, which was absent in Tian resilient rats. Tian decreased myo-inositol and increased TCA cycle intermediates, amino acids, and cholesterol and its metabolite. As key molecules of divergence between Tian effectiveness and resilience, metabolomics revealed myo-inositol, GABA, cholesterol, and its metabolite. A significant moderate positive correlation between myo-inositol and immobility was revealed. Tian probably acted by upregulating NMDAR's and α2 adrenergic receptors (AR) or norepinephrine transporter in both control and stressed animals.
CONCLUSION: Metabolomics revealed several dysregulations underlying CSIS-induced depressive-like behavior and responsiveness to Tian, predominantly converging into NMDAR-mediated glutamate and myo-inositol signalization and GABA inhibitory pathways.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Depression; GC × GC–MS; Hippocampus; Metabolomics; Tianeptine

Mesh:

Substances:

Year:  2022        PMID: 35776189     DOI: 10.1007/s00213-022-06180-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.415


  70 in total

1.  Evaluation of Myo-Inositol as a Potential Biomarker for Depression in Schizophrenia.

Authors:  Joshua Chiappelli; Laura M Rowland; S Andrea Wijtenburg; Florian Muellerklein; Malle Tagamets; Robert P McMahon; Frank Gaston; Peter Kochunov; L Elliot Hong
Journal:  Neuropsychopharmacology       Date:  2015-02-27       Impact factor: 7.853

Review 2.  Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain.

Authors:  I Björkhem
Journal:  J Intern Med       Date:  2006-12       Impact factor: 8.989

3.  Reduced myo-inositol levels in cerebrospinal fluid from patients with affective disorder.

Authors:  A I Barkai; D L Dunner; H A Gross; P Mayo; R R Fieve
Journal:  Biol Psychiatry       Date:  1978-02       Impact factor: 13.382

4.  Metabolomics and its potential in drug development.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  Biochem Pharmacol       Date:  2012-08-23       Impact factor: 5.858

5.  Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole.

Authors:  M Banasr; G M I Chowdhury; R Terwilliger; S S Newton; R S Duman; K L Behar; G Sanacora
Journal:  Mol Psychiatry       Date:  2008-09-30       Impact factor: 15.992

6.  Does increasing the ratio of AMPA-to-NMDA receptor mediated neurotransmission engender antidepressant action? Studies in the mouse forced swim and tail suspension tests.

Authors:  Jesper T Andreasen; Mikko Gynther; Allan Rygaard; Trine Bøgelund; Simon D Nielsen; Rasmus P Clausen; Jesper Mogensen; Darryl S Pickering
Journal:  Neurosci Lett       Date:  2013-05-02       Impact factor: 3.046

7.  Decreased Prostaglandin D2 Levels in Major Depressive Disorder Are Associated with Depression-Like Behaviors.

Authors:  Cuilin Chu; Hui Wei; Wanwan Zhu; Yan Shen; Qi Xu
Journal:  Int J Neuropsychopharmacol       Date:  2017-09-01       Impact factor: 5.176

8.  Antidepressant drugs act by directly binding to TRKB neurotrophin receptors.

Authors:  Plinio C Casarotto; Mykhailo Girych; Senem M Fred; Vera Kovaleva; Rafael Moliner; Giray Enkavi; Caroline Biojone; Cecilia Cannarozzo; Madhusmita Pryiadrashini Sahu; Katja Kaurinkoski; Cecilia A Brunello; Anna Steinzeig; Frederike Winkel; Sudarshan Patil; Stefan Vestring; Tsvetan Serchov; Cassiano R A F Diniz; Liina Laukkanen; Iseline Cardon; Hanna Antila; Tomasz Rog; Timo Petteri Piepponen; Clive R Bramham; Claus Normann; Sari E Lauri; Mart Saarma; Ilpo Vattulainen; Eero Castrén
Journal:  Cell       Date:  2021-02-18       Impact factor: 41.582

Review 9.  Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation: systematic review.

Authors:  Katharine Barnard; Robert C Peveler; Richard I G Holt
Journal:  Diabetes Care       Date:  2013-10       Impact factor: 19.112

10.  NMDA Receptor Antagonists for Treatment of Depression.

Authors:  Zeynep Ates-Alagoz; Adeboye Adejare
Journal:  Pharmaceuticals (Basel)       Date:  2013-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.